Back to Search Start Over

[ALK inhibitor].

Authors :
Mano H
Source :
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2011 Jan; Vol. 38 (1), pp. 27-30.
Publication Year :
2011

Abstract

While lung cancer is the leading cause of cancer deaths worldwide, the molecular mechanism underlying its carcinogenesis is mainly unknown. We have discovered a small, fusion-type tyrosine kinase EML4-ALK that is generated through a tiny inversion within the short arm of human chromosome 2. Transgenic mice expressing EML4-ALK in lung developed hundreds of lung cancer nodules soon after birth, but such nodules were readily eradicated upon treatment with an ALK inhibitor. Clinical trials for EML4-ALK-positive lung cancer with an ALK inhibitor is ongoing, with its interim results being highly promising.

Details

Language :
Japanese
ISSN :
0385-0684
Volume :
38
Issue :
1
Database :
MEDLINE
Journal :
Gan to kagaku ryoho. Cancer & chemotherapy
Publication Type :
Academic Journal
Accession number :
21368458